Athos Commerce vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI ecommerce optimization platform from Klevu + Searchspring merger. Backed by PSG. Search, merchandising, personalization. Launched 2025, San Antonio.
About
Athos Commerce is an AI-powered ecommerce optimization platform launched in 2025 and based in San Antonio, Texas. The company was formed through the strategic merger of Klevu, a leader in AI-native search and product discovery, and Searchspring, a well-established ecommerce search and merchandising platform. Together they created a unified solution backed by PSG, a growth-focused private equity firm specializing in software businesses, combining both companies' existing customer bases and technical capabilities.\n\nThe combined platform delivers AI-driven site search, merchandising, personalization, and product recommendations across ecommerce storefronts. Athos Commerce serves mid-market and enterprise retailers by surfacing the right products to the right shoppers at the right moment — reducing bounce rates, improving conversion, and increasing average order value. Its differentiated position comes from pairing Klevu's AI-native search architecture with Searchspring's deep merchandising toolset and established retailer relationships.\n\nAthos Commerce enters the market as a scaled, well-capitalized competitor in the ecommerce experience layer, a space contested by Bloomreach, Coveo, and Algolia. The merger pools a substantial joint customer base from both legacy brands and positions Athos as a full-stack discovery and personalization partner for retailers seeking to modernize their ecommerce stacks. Its PSG backing provides both operational resources and M&A capacity to accelerate further category consolidation.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.